Polyoxypregnane Ester Derivatives and Lignans from *Euphorbia gossypina* var. *coccinea* Pax.

Reham Hammadi 1, Norbert Kúsz 1, Csilla Zsuzsanna Dávid 1, Peter Waweru Mwangi 2, Róbert Berkecz 3, Nikoletta Szemerédi 4, Gabriella Spengler 4, Judit Hohmann 1,5 and Andrea Vasas 1,* 1

1 Department of Pharmacognosy, University of Szeged, Eötvös u. 6, 6720 Szeged, Hungary; reham.hammadi@pharmacognosy.hu (R.H.); kusznorbert@gmail.com (N.K.); davidzsuzsanna88@gmail.com (C.Z.D.); hohmann.judit@szte.hu (J.H.)

2 School of Biological Sciences, University of Nairobi, P.O. Box 30197, Nairobi 00100, Kenya; waweruk2001@gmail.com

3 Institute of Pharmaceutical Analysis, University of Szeged, 6720 Szeged, Hungary; berkecz.robert@szte.hu

4 Department of Medical Microbiology, Albert Szent-Györgyi Health Center, Albert Szent-Györgyi Medical School, University of Szeged, 6725 Szeged, Hungary; szemeredi.nikoletta@med.u-szeged.hu (N.S.); spengler.gabriella@med.u-szeged.hu (G.S.)

5 Interdisciplinary Centre of Natural Products, University of Szeged, Eötvös u. 6, 6720 Szeged, Hungary

Correspondence: vasas.andrea@szte.hu; Tel.: +36-62546451

Abstract: From the aerial parts of *Euphorbia gossypina* var. *coccinea* Pax., eight new pregnane glycosides (euphogossypins A–H, 1–8) of the cyananforidine and deacetylmethylaplexigenin aglycons, two new lignans (gossypilignans A and B, 9 and 10), and four known compounds, namely, the pregnane 12-O-benzyloxideacxylmethylaplexigenin (11), the lignan 9α-hydroxyxypinoresinol (12), and the flavonoids naringenin (13) and querectrin (14) were isolated. The structure elucidation of the new compounds was carried out by a spectroscopic analysis, including HRMS, 1D (1H, 13C JMOD), and 2D NMR (HSQC, 1H–1H COSY, HMBC, and NOESY) experiments. The obtained pregnane glycosides were substituted with acetyl and benzoyl ester moieties, and sugar chains containing thevetose, cymarose, digitoxose, and glucose monosaccharides. All of the compounds are described for the first time from *E. gossypina* var. *coccinea*. The isolated pregnanes and lignans were tested for their antiproliferative activity on HeLa cells using the MTT assay; the compounds exerted no significant effect against the tumor cells.

Keywords: Euphorbiaceae; *Euphorbia gossypina* var. *coccinea*; pregnane glycosides; lignans; flavonoids

1. Introduction

Plants belonging to the genus *Euphorbia* are known to possess considerable chemical, medicinal, and economic importance [1]. Terpenes, including diterpenes and triterpenes, steroids, cerebrosides, glycerols, and phenolic compounds are characteristic constituents of *Euphorbia* species [2]. In the course of our work focusing on the isolation of special metabolites from various *Euphorbia* species, the chemical composition of *Euphorbia gossypina* var. *coccinea* Pax. (Euphorbiaceae) was thoroughly investigated [3]. The aim of our work was the identification of the special metabolites of the plant. This plant is a perennial, much-branched, succulent, herbaceous, evergreen shrub native to Kenya and Tanzania. Preparations of *E. gossypina* have long been used in traditional medicine for the treatment of swollen legs and general body pain. Moreover, it is applied as eye drops in the treatment of conjunctivitis and warts [4]. The diluted latex of small twigs is taken to treat laryngitis [5]. In Somalia, the latex is applied to treat mange in livestock [6]. There is no literature data on *Euphorbia gossypina* var. *coccinea*.

Herein, we report the isolation and structure elucidation of fourteen compounds, among them being eight new polyoxypregnane ester derivatives (euphogossypins A–
Herein, we report the isolation and structure elucidation of fourteen compounds, including the pregnane 12-O-benzoyldeacylmetaplexigenin (11), the lignan 9α-hydroxyypinoresinol (12), and the flavonoids naringenin (13) and quercitrin (14) from E. gossypina var. coccinea.

Pregnane glycosides are C21 steroidal natural compounds, in which the pregnane part is attached to different sugars. These compounds demonstrate a fair degree of diversity in their aglycone part with different numbers and types of sugar units being attached to the aglycone at position C-3 [7]. The sugar part of these compounds can be a mono- or disaccharide, or an oligosaccharide chain arranged mainly linearly to the pregnane skeleton through an acetal linkage. The characteristic monosaccharides of pregnane glycosides are D-glucose, L-rhamnose, D-cymarose, D-oleanrose, D-allose, and D-digitoxose. The occurrence of pregnane glycosides is characteristic of the Asclepiadaceae, Apocynaceae, Malpighiaceae, Ranunculaceae, and Zygophyllaceae families [8]. Pregnane glycosides are reported to possess noteworthy pharmacological properties, such as immunosuppressant, cytotoxic, antidepressant, anti-inflammatory, antioxidant, antibacterial, antifungal, and antiproliferative activities [8]. Therefore, the isolated compounds were tested for their antiproliferative activity against the HeLa cell line using the MTT assay.

2. Results and Discussion

2.1. Isolation of Compounds

The dried and ground aerial parts of the plant were extracted with methanol. After evaporation of the methanol, the extract was dissolved in 50% aqueous methanol, and a solvent–solvent partition was performed with n-hexane, CHCl3, and EtOAc. The CHCl3 extract was separated by normal (NP) and reversed-phase (RP) vacuum liquid chromatography (VLC), and then it was purified by preparative thin layer chromatography (prep. TLC) and high-performance liquid chromatography (HPLC) to yield eight new pregnane glycosides (1–8), two new lignans (9, 10), one known pregnane and one lignan, and two known flavonoids (Figure 1).

| Compound | R1 | R2 | Sugar 1 | Sugar 2 | Sugar 3 | Sugar 4 |
|----------|----|----|---------|---------|---------|---------|
| 1        | Bz | Cym| Cym     | Thv     |         |         |
| 2        | Bz | Dig| Dig     | Thv     |         |         |
| 3        | Bz | Cym| Dig     | Thv     |         |         |
| 4        | Bz | Cym| Cym     | Thv     | Glc     |         |
| 5        | Bz | Dig| Dig     | Thv     | Glc     |         |
| 6        | Bz | Cym| Dig     | Thv     | Glc     |         |
| 7        | Ac | Dig| Dig     | Thv     |         |         |
| 8        | H  | Cym| Dig     | Thv     |         |         |

Sugar 3 (1–3, 7, 8) and sugar 4 (4–6) are in terminal position.
2.2. Structure Elucidation of the Compounds

The structure determination of the isolated compounds was carried out by an extensive spectroscopic analysis, including one- and two-dimensional NMR and HRMS measurements. Compound 1 was obtained as a white amorphous powder. Its molecular formula was determined as C_{49}H_{72}O_{17} by the HRESIMS ion at m/z 955.4660 [M + Na]^+ (calcd for C_{49}H_{72}O_{17}Na, 955.4662). The $^1$H NMR spectrum of 1 showed the resonances of three anomic protons at $\delta_H$ 4.85 (dd, $J = 2.0$ and 9.0 Hz), 4.76 (dd, $J = 1.8$ and 9.5 Hz), and 4.30 (d, $J = 7.8$ Hz), three methoxy groups at $\delta_H$ 3.42, 3.44, and 3.65 (each 3H, s), and three secondary methyl groups at $\delta_H$ 1.22 (d, $J = 6.3$ Hz), 1.27 (d, $J = 6.2$ Hz), and 1.31 (d, $J = 6.2$ Hz), suggesting the presence of a trisaccharide unit in 1 composed of deoxymethyl sugars. Moreover, the $^1$H NMR spectrum contained signals ascribable to three methyl groups displayed at $\delta_H$ 1.12 (3H, s), 1.54 (3H, s), and 2.06 (3H, s), and to an olefinic proton at $\delta_H$ 7.58 (1H, br s). The proton signals at $\delta_H$ 7.93 (2H, dd), 7.43 (2H, t), and 7.55 (1H, t) showed the presence of a benzoyl group in the molecule. The JMOD spectrum indicated that compound 1 contained two carbonyls, seven non-protonated carbons (of which three were oxygenated), twenty-two methines (of which eleven were oxygenated), nine methylenes, and nine methyl carbons (of which three were methoxy). The $^1$H and $^{13}$C JMOD NMR data dictated that 1 was a pregnane glycoside. Of these, 21 carbons were assigned to a pregnane skeleton, 7 to a benzoyl function, and 19 to a trisaccharide moiety. The HMBC correlations between H-19 ($\delta_H$ 1.12) and C-1 ($\delta_C$ 38.9), C-5 ($\delta_C$ 140.8), C-9 ($\delta_C$ 43.8), and C-10 ($\delta_C$ 37.3) suggested the position of a double bond at C-5/C-6. The HMBC correlations between H-18 ($\delta_H$ 1.54) and C-12 ($\delta_C$ 73.3), C-14 ($\delta_C$ 88.1), and C-17 ($\delta_C$ 91.6), between H-21 ($\delta_H$ 2.06) and C-17 ($\delta_C$ 91.6), and H-6 ($\delta_H$ 5.38) and C-8 ($\delta_C$ 74.4) demonstrated the positions of hydroxy groups at C-8, C-14, and C-17 (Figure 2). The aglycone moiety of 1 was, therefore, determined to be 12β-benzoyloxy-3β,8β,14β,17β-tetrahydroxypregn-5-ene (cyananforidine), a C/D-cis-polyoxypregnane ester [9]. The relative configuration of the molecule was determined by the analysis of NOESY correlations and literature data of similar structures reported previously.
The aglycone of 1 was supposed to have the same configuration as those of pregnanes isolated from Gymnema sylvestre [10]. The multiplicity of H-12 (δH 4.83 (dd, J = 4.2, 11.9 Hz)) implied that the configuration of H-12 was axial (α-configuration, Figure 2). The NOESY correlations between H-3 (δH 3.57), Hα-1 (δH 1.89), and Hα-4 (δH 2.40), and between H-12 (δH 4.83) and H-9 (δH 1.59) determined the configurations of the oxygenated groups at C-3 and C-12 to be β. NOESY correlations detected between Hβ-1 (δH 1.13) and Hβ-4 (δH 2.29) showed the α-position of these protons. The C-12 benzoyl group was confirmed by HMBC correlation from H-12 (δH 4.83) to the benzoyl carbonyl C-1. The large coupling constants between the H-1 and H-2 of monosaccharide moieties, and the HMBC correlations between Thv H-1 (δH 4.30) and Cym II C-4 (δC 82.8), Cym II H-1 (δH 4.76) and Cym I C-4 (δC 82.7), and between Cym I H-1 (δH 4.85) and aglycone C-3 (δC 78.0) indicated the sugar linkages as β-D-thevetopyranosyl-(1→4)β-D-cymaropyranosyl-(1→4)-β-D-cymaropyranoside and at C-3 of aglycone. Based on the above evidence, the structure of 1 was elucidated as cyananforidine 3-O-β-D-thevetopyranosyl-(1→4)-β-D-cymaropyranosyl-(1→4)-β-D-cymaropyranoside, a new compound named euphogossypin A.

Compound 2 was isolated as a white amorphous powder. Its 1H and JMOD spectra exhibited the characteristic signals of a pregnane aglycone, one benzoyl unit, and three sugar moieties (Table 1). In addition, NMR data of 2 were similar to those of euphogossypin A (1), except for the difference in sugar units at C-3. A careful analysis of NMR data led to the conclusion that two cymarose units were replaced by two digitoxose monosaccharides. The HMBC correlations between Thv H-1 (δH 4.82) and Dig II C-4 (δC 84.1), Dig II H-1 (δH 5.41) and Dig I C-4 (δC 83.9), and between Dig I H-1 (δH 5.48) and aglycone C-3 (δC 78.1) confirmed the sugar linkages to be 3-O-β-D-thevetopyranosyl-(1→4)-β-D-digitoxopyranosyl-(1→4)-β-D-digitoxopyranosyl-(1→4)-β-D-digitoxopyranoside. Consequently, compound 2 was identified as a new compound, cyananforidine 3-O-β-D-thevetopyranosyl-(1→4)-β-D-digitoxopyranosyl-(1→4)-β-D-digitoxopyranoside, named euphogossypin B.
Table 1. The $^1$H and $^{13}$C NMR data for compounds 1-3.

| Atom | $^1$H (J in Hz) | $^13$C | $^1$H (J in Hz) | $^13$C | $^1$H (J in Hz) | $^13$C |
|------|----------------|-------|----------------|-------|----------------|-------|
| 1    | 1.13, m, α/1.89, m, β  | 38.9, CH$_2$ | 1.14, m, α/1.83, m, β | 39.4, CH$_2$ | 1.14, m, α/1.83 m, β | 39.8, CH$_2$ |
| 2    | 1.62, m, β/1.92, m, α  | 29.1, CH$_2$ | 1.82, m, β/2.11, m, α | 30.3, CH$_2$ | 1.58, m, β/1.87 m, α | 30.2, CH$_2$ |
| 3    | 3.57, m           | 78.0, CH   | 3.89, m          | 78.1, CH   | 3.54, m          | 79.3, CH   |
| 4    | 2.29, m, β/2.40, m, α  | 38.9, CH$_2$ | 2.43, m, β/2.55, m, α  | 39.7, CH$_2$ | 2.22, m; 2.38 dd  | (3.4, 12.7) |
| 5    | -              | 140.8, C   | -              | 139.9, C   | -              | 140.3, C   |
| 6    | 5.38, br s       | 117.8, CH  | 5.31, br s      | 119.6, CH  | 5.36, br d (4.7)  | 119.7, CH  |
| 7    | 2.22, m          | 34.4, CH$_2$ | 2.38, m/2.50, m  | 35.2, CH$_2$ | 2.12–2.22 m      | 35.2, CH$_2$ |
| 8    | -              | 74.4, C   | -              | 74.8, C   | -              | 75.2, C   |
| 9    | 1.59, m          | 43.8, CH   | 1.80, m         | 44.9, CH   | 1.59 m          | 45.1, CH   |
| 10   | -              | 37.3, C   | -              | 37.9, C   | -              | 38.2, C   |
| 11   | 1.94, m          | 24.3, CH$_2$ | 2.21, m, α/2.36, m, β | 25.5, CH$_2$ | 1.81, m, α/2.00, m, β | 25.5, CH$_2$ |
| 12   | 4.83, dd (4.2, 11.9) | 73.3, CH   | 5.36, dd (4.3, 11.5)  | 77.5, CH   | 4.83 dd (4.3, 11.9)  | 74.7, CH   |
| 13   | -              | 58.5, C   | -              | 58.8, C   | -              | 59.1, C   |
| 14   | -              | 88.1, C   | -              | 90.0, C   | -              | 90.0, C   |
| 15   | 2.03, m          | 33.4, CH$_2$ | 2.14–2.21, m    | 34.3, CH$_2$ | 1.92, m; 2.06, * m  | 34.3, CH$_2$ |
| 16   | 1.92, m, β/2.85, m, α | 32.1, CH$_2$ | 2.07, m/3.27, m  | 33.7, CH$_2$ | 1.73, m, β/2.87, m, α | 33.5, CH$_2$ |
| 17   | -              | 91.6, C   | -              | 93.0, C   | -              | 93.1, C   |
| 18   | 1.54, s          | 9.7, CH$_2$ | 2.10, s        | 11.3, CH$_2$ | 1.67, s    | 10.6, CH$_2$ |
| 19   | 1.12, s          | 18.7, CH$_2$ | 1.34, s       | 18.6, CH$_2$ | 1.16, s    | 18.6, CH$_2$ |
| 20   | -              | 205.5, C  | -              | 210.6, C  | -              | 212.2, C  |
| 21   | 2.06, s          | 27.5, CH$_2$ | 2.37, s        | 28.2, CH$_2$ | 2.05, s    | 27.8, CH$_2$ |
| Bz   | -              | -        | -              | -        | -              | -        |
| 1$'$ | -              | 165.5, C  | -              | 165.8, C  | -              | 166.7, C  |
| 2$'$ | -              | 130.1, C  | -              | 131.8, C  | -              | 131.6, C  |
| 3$'$ | 7.93, dd (1.1, 8.2) | 129.7, CH  | 8.31, d (7.8)  | 130.4, CH  | 7.95, d (7.9)  | 130.5, CH  |
| 4$'$ | 7.43, t (8.0)    | 128.6, CH  | 7.49, t (7.7)  | 129.4, CH  | 7.48, dd (7.9, 7.4)  | 129.6, CH  |
| 5$'$ | 7.55, t (8.1)    | 133.3, CH  | 7.59, t (7.7)  | 133.7, CH  | 7.61, t (7.4)  | 134.3, CH  |
| Cym I | 4.85, dd (2.0, 9.0) | 96.2, CH   | 5.48, d (9.4)  | 96.9, CH   | 4.87, dd (1.9, 8.9)  | 97.2, CH   |
| 1    | 1.58, m, a/2.08, m, e | 35.7, CH$_2$ | 2.05, m/2.43, m  | 39.5, CH$_2$ | 1.54, m, a/2.06, m, e | 36.7, CH$_2$ |
| 3    | 3.80, m          | 77.2, * CH | 4.65, m        | 68.0, CH   | 3.85, m        | 78.6, CH   |
| 4    | 3.21, dd (3.0, 9.6) | 82.7, CH   | 3.53, m        | 83.9, CH   | 3.24, m        | 83.9, CH   |
| 5    | 3.84, m          | 68.7, CH   | 4.31, m        | 69.1, CH   | 3.81, m        | 70.0, CH   |
| 6    | 1.22, d (6.3)    | 18.3, CH$_3$ | 1.45, d (6.0)  | 19.1, CH$_3$ | 1.20, d (6.2)  | 18.5, CH$_3$ |
| 3-OME | 3.42, s *        | 58.1, * CH$_3$ | 3.44, s        | 58.5, CH$_3$ | 3.37, s        | 58.5, CH$_3$ |
| Cym II | 4.76, dd (1.8, 9.5) | 99.7, CH   | 5.41, d (9.6)  | 100.3, CH  | 4.89, dd (1.7, 9.1)  | 101.0, CH  |
| 1    | 1.65, m, a/2.16, m, e | 35.3, CH$_2$ | 2.00, m, a/2.43, m, * e | 39.4, CH$_2$ | 1.71, m, a/2.02, m, e | 38.8, CH$_2$ |
| 3    | 3.78, m          | 77.1,* CH | 4.70, m        | 68.3, CH   | 4.21, m        | 68.6, CH   |
| 4    | 3.26, dd (2.9, 9.6) | 82.8, CH   | 3.60, m        | 84.1, CH   | 3.24, * m      | 83.8, CH   |
| 5    | 3.90, m          | 68.4, CH   | 4.37, m        | 69.5, CH   | 3.87, m        | 69.5, CH   |
| 6    | 1.27, d (6.2)    | 18.6, CH$_3$ | 1.59, d (6.1)  | 19.0, CH$_3$ | 1.31, d (6.2)  | 18.6, CH$_3$ |
| 3-OME | 3.44, s *        | 58.2, * CH$_3$ | 3.44, s        | 58.5, CH$_3$ | 3.37, s        | 58.5, CH$_3$ |

* in CDCl$_3$ (1), pyridine-d$_5$ (2), methanol-d$_4$ (3), $^*$ interchangeable signals; $^*$ overlaps with solvent signal.
The molecular formula of 3 was determined as C_{48}H_{70}O_{17} by the HRESIMS molecular ion at m/z 941.4508 [M + Na]^+ (calcld for C_{48}H_{70}O_{17}Na 941.4510). The ^1H and JMOD data (Table 1) suggested that the structure of 3 was similar to those of 1 and 2, except for the difference in monosaccharide units in the C-3 sugar chain. The sugar moieties were found to be D-cymarose, D-digitoxose, and D-thevetose. The sugar linkages (β-D-thevetopyranosyl-(1→4)-β-D-digitoxopyranosyl-(1→4)-β-D-cymaropyranoside) to each other and to the pregnane skeleton were confirmed by the HMBC correlations from Thv H-1 (δ_H 4.35) to Dig C-4 (δ_C 83.8), from Dig H-1 (δ_H 4.89) to Cym C-4 (δ_C 83.9), and from Cym H-4 (δ_H 3.24) to C-3 (δ_C 79.3). Similarly to those of 1 and 2, the aglycone was found to be 12β-benzoyloxy-3β,8β,14β,17β-tetrahydroxyregn-5-ene (cyananforidine). Consequently, the structure of 3 was determined as cyananforidine 3-0-β-D-thevetopyranosyl-(1→4)-β-D-digitoxopyranosyl-(1→4)-β-D-cymaropyranoside and named euphogossypin C.

HRESIMS and NMR data of compounds 4–6 suggested that they were tetrasaccharide derivatives due to the presence of four anomeric carbon and proton signals, one more than observed for compounds 1–3. The additional sugar unit was identified as D-glucopyranose (Table 2). The polyoxy pregnane ester aglycone was the same as in compounds 1–3. The large coupling constant between H-1 and H-2 of the glucose unit, and the HMBC correlations between Glc H-1 (δ_H 4.43) and Thv C-4 (δ_C 82.8) in 4–6, indicated the sugar linkages as β-D-glucopyranosyl-(1→4)-β-D-thevetopyranosyl-(1→4)-β-D-cymaropyranosyl-(1→4)-β-D-cymaropyranoside in 4, β-D-glucopyranosyl-(1→4)-β-D-thevetopyranosyl-(1→4)-β-D-digitoxopyranosyl-(1→4)-β-D-cymaropyranoside in 5, and β-D-glucopyranosyl-(1→4)-β-D-thevetopyranosyl-(1→4)-β-D-digitoxopyranosyl-(1→4)-β-D-cymaropyranoside in 6. Based on the above evidence, the structure of 4 was deduced to be cyananforidine β-D-glucopyranosyl-(1→4)-β-D-thevetopyranosyl-(1→4)-β-D-cymaropyranoside and was named euphogossypin D. 5 was determined as cyananforidine β-D-glucopyranosyl-(1→4)-β-D-thevetopyranosyl-(1→4)-β-D-digitoxopyranosyl-(1→4)-β-D-cymaropyranoside and named euphogossypin E, and 6 was characterized as cyananforidine β-D-glucopyranosyl-(1→4)-β-D-thevetopyranosyl-(1→4)-β-D-digitoxopyranosyl-(1→4)-β-D-cymaropyranoside and named euphogossypin F.

Table 2. The ^1H and ^13C NMR data for compounds 4–6 in CD$_3$OD.

| Atom | δ_H (f in Hz) | δ_C | δ_H (f in Hz) | δ_C | δ_H (f in Hz) | δ_C |
|------|---------------|------|---------------|------|---------------|------|
| 4    | 1.14, m, α/1.85, m, β | 39.8, CH$_2$ | 1.16, m, α/1.85, m, β | 39.8, CH$_2$ | 1.16, m, α/1.84, m, β | 39.8, CH$_2$ |
| 2    | 1.60, m, *β/1.88, m, α | 30.2, CH$_2$ | 1.61, m, *β/1.88, m, α | 30.1, CH$_2$ | 1.59, m, β/1.87, m, α | 30.2, CH$_2$ |
| 3    | 3.55, m | 79.3, CH | 3.56, m | 79.3, CH | 3.54, m | 79.3, CH |
| 4    | 2.23, m, β/2.38, m, α | 39.8, CH$_2$ | 2.23, m, 2.40 dd (3.5, 12.7) | 39.8, CH$_2$ | 2.22, m, β/2.38, m, α | 39.8, CH$_2$ |
| 5    | - | 140.2, C | - | 140.3, C | - | 140.3, C |
| 6    | 5.37, br d (4.6) | 119.7, CH | 5.37, br d (4.6) | 119.6, CH | 5.36, br s | 119.7, CH |
| 7    | 2.13–2.22, m | 35.2, CH$_2$ | 2.14-2.22 m | 35.2, CH$_2$ | 2.14-2.21, m | 35.2, CH$_2$ |
| 8    | - | 75.0, C | - | 75.0, C | - | 75.0, C |
| 9    | 1.61, m * | 45.1, CH | 1.61 m * | 45.1, CH | 1.60, m | 45.1, CH |
| 10   | - | 38.2, C | - | 38.2, C | - | 38.2, C |
| 11   | 1.83, m, α/2.02, m, β | 25.5, CH$_2$ | 1.83, m, α/2.02, m, β | 25.4, CH$_2$ | 1.82, m, α/2.01, m, β | 25.4 CH$_2$ |
| 12   | 4.83, dd * | 74.7, CH | 4.82 dd (4.3, 11.9) | 74.7, CH | 4.82, dd (overlaps) | 73.3, CH |
| 13   | - | 59.1, C | - | 59.1, C | - | 59.1, C |
| 14   | - | 90.0, C | - | 90.0, C | - | 90.0, C |
| 15   | 1.94, m, 2.07, m | 34.3, CH$_2$ | 1.94, m, 2.08, m | 34.3, CH$_2$ | 1.93, m, 2.07, m | 34.3, CH$_2$ |
| 16   | 1.75, m, β/2.87, m, α | 33.5, CH$_2$ | 1.75, m, β/2.87, m, α | 33.5, CH$_2$ | 1.74, m, β/2.87, m, α | 33.5, CH$_2$ |
The NMR data of compound 7 were very similar to that of 2, with the only difference between them being the replacement of the benzoyl moiety into an acetyl substituent at C-12. Therefore, the aglycone of 7 was identified as metaplexigenin (Table 3) [11]. The connecting sugar chain was determined as β-D-thevetopyranosyl-(1→4)-β-D-digitoxopyranosyl-(1→4)-β-D-digitoxopyranoside based on the 1D and 2D NMR spectral data. Compound 7 was, thus, characterized as metaplexigenin β-D-thevetopyranosyl-(1→4)-β-D-digitoxopyranosyl-(1→4)-β-D-digitoxopyranoside and named euphogossypin G.
Table 3. The $^1$H and $^{13}$C NMR data for compounds 7 and 8 in CDCl$_3$.

| Atom | $\delta$H (J in Hz) | $\delta$C | $\delta$H (J in Hz) | $\delta$C |
|------|---------------------|-----------|---------------------|-----------|
| 1    | 1.10, m, $\alpha$/1.86, m, $\beta$ | 39.0, *CH$_2$ | 1.08, m, $\alpha$/1.87, m, $\beta$ | 39.0, *CH$_2$ |
| 2    | 1.64, m, $\beta$/1.93, m, $*\alpha$ | 29.0, CH$_2$ | 1.66, m, $\beta$/1.94, m, $\alpha$ | 29.2, CH$_2$ |
| 3    | 3.57, m | 78.1, CH | 3.55, m | 78.1, CH |
| 4    | 2.29, m, $\beta$/2.41, m, $*\alpha$ | 39.0, *CH$_2$ | 2.30, m, $\beta$/2.38, m, $\alpha$ | 39.1, *CH$_2$ |
| 5    | - | 141.4, C | - | 140.8, C |
| 6    | 5.35, br s | 117.5, CH | 5.36, br s | 117.9, CH |
| 7    | 2.20, m | 34.3, CH$_2$ | 2.18, m | 34.5, CH$_2$ |
| 8    | - | 74.7, C | - | 74.5, C |
| 9    | 1.52, m | 43.9, CH | 1.46, dd (3.2, 13.1) | 44.4, CH |
| 10   | - | 37.4, C | - | 37.3, C |
| 11   | 1.78, m | 24.4, CH$_2$ | 1.60, m, $\alpha$/1.90, m, $\beta$ | 28.2, CH$_2$ |
| 12   | 4.51, dd (5.8, 10.3) | 72.7, CH | 5.68, m | 69.7, CH |
| 13   | - | 57.8, C | - | 61.1, C |
| 14   | - | 88.3, C | - | 88.0, C |
| 15   | 1.93, m * | 32.8, CH$_2$ | 1.94, m * | 34.3, CH$_2$ |
| 16   | 1.83, m, $\beta$/2.87, m, $\alpha$ | 32.4, CH$_2$ | 1.92, m, $\beta$/2.75, m, $\alpha$ | 33.7, CH$_2$ |
| 17   | - | 91.9, C | - | 92.1, C |
| 18   | 1.42, s | 9.4, CH$_3$ | 1.27, s | 7.9, CH$_3$ |
| 19   | 1.12, s | 18.9, CH$_3$ | 1.16, s | 18.9, CH$_3$ |
| 20   | - | 209.4, C | - | 213.9, C |
| 21   | 2.24, s | 27.4, CH$_3$ | 2.34, s | 28.4, CH$_3$ |
| 12-OAc | - | 170.0, C | - | 170.0, C |
| 14-OH | 3.94, s | 4.12, br s | - | - |
| 17-OH | 4.42, s | 4.61, br s | - | - |

**Dig I**

| Atom | $\delta$H (J in Hz) | $\delta$C | $\delta$H (J in Hz) | $\delta$C |
|------|---------------------|-----------|---------------------|-----------|
| 1    | 4.92, dd (1.7, 9.3) | 96.1, CH | 4.85, br d (9.5) * | 96.3, CH |
| 2    | 1.72, m, $\alpha$/2.08, m, e | 37.3, CH$_2$ | 1.59, m; 2.09, m | 35.9, CH$_2$ |
| 3    | 4.24, m * | 66.7, CH | 3.81, m | 77.3, CH |
| 4    | 3.23, dd (3.0, 9.4) | 82.8, CH | 3.24, dd (2.9, 9.6) | 82.9, CH |
| 5    | 3.79, dq (6.3, 9.4) | 68.3, CH | 3.85, m * | 68.7, CH |
| 6    | 1.23, d (6.3) | 18.4, CH$_3$ | 1.22, d (6.2) | 18.4, CH$_3$ |

**Dig II**

| Atom | $\delta$H (J in Hz) | $\delta$C | $\delta$H (J in Hz) | $\delta$C |
|------|---------------------|-----------|---------------------|-----------|
| 1    | 4.91, dd (1.7, 9.3) | 98.5, CH | 4.85, br d (9.5) * | 99.6, CH |
| 2    | 1.75, m, $\alpha$/2.14, m, e | 37.0, CH$_2$ | 1.77, m, $\alpha$/2.15, m, e | 37.1, CH$_2$ |
| 3    | 4.23, m * | 66.8, CH | 4.21, m | 66.9, CH |
| 4    | 3.26, dd (2.9, 9.4) | 83.2, CH | 3.27, dd (3.0, 9.4) | 83.4, CH |
| 5    | 3.90, dq (6.2, 9.4) | 68.2, CH | 3.86, m * | 67.9, CH |
| 6    | 1.29, d (6.2) | 18.5, CH$_3$ | 1.29, d (6.2) | 18.5, CH$_3$ |

**3-OMe**

| Atom | $\delta$H (J in Hz) | $\delta$C | $\delta$H (J in Hz) | $\delta$C |
|------|---------------------|-----------|---------------------|-----------|
| 1    | 3.47, m | 74.7, CH | 3.45, m | 74.7, CH |
| 2    | 3.11, t (9.0) | 85.4, CH | 3.10, t (9.0) | 88.3, CH |
| 3    | 3.19, t (9.0) | 74.8, CH | 3.19, t (9.0) | 74.8, CH |
| 4    | 3.40, m | 72.2, CH | 3.39, dd (6.1, 9.0) | 72.2, CH |
| 5    | 1.32, d (6.1) | 17.9, CH$_3$ | 1.31, d (6.1) | 17.9, CH$_3$ |
| 3-OH | 3.66, s | 60.9, CH$_3$ | 3.66, s | 60.8, CH$_3$ |

*# interchangeable signals.

Compound 8 wore the same C-3 trisaccharide sugar chain, $\beta$-D-thevetopyranosyl-(1$\rightarrow$4)-$\beta$-D-digitoxopyranosyl-(1$\rightarrow$4)-$\beta$-D-cymaropyranoside, as 3 (Table 3). By the NMR data, it was determined to be a deacetylmetaplexigenin derivative and named euphoggossypin H.
Gossypilignan A (9) was obtained as a pale yellow, amorphous solid. The molecular formula of 9 was determined as C_{22}H_{30}O_{7} from its HRESIMS ion observed at m/z 429.1889 [M + Na]^+ (calcd for C_{22}H_{30}O_{7}Na 429.1884). The 1H and 13C NMR data indicated the presence of four methoxyl signals (δ_H 2 × 3.82, s, and 2 × 3.83, s; δ_C 4 × 56.8), two methyl (δ_H 0.68, d, J = 6.9 Hz, and 0.76, d, J = 7.0 Hz; δ_C 10.0 and 12.1), one methylene (δ_H 3.35 and 3.45; δ_C 67.3), and three methine groups (δ_C 37.0, 37.2, and 57.9) (Table 4). Additionally, the 1H NMR spectrum of 9 showed aromatic protons at δ_H 6.64, s and 6.66, s (2H each), implying that the aromatic rings were tetrasubstituted. The 13C NMR spectrum of 9 also supported the presence of six oxygenated aromatic carbons at δ_C 149.1, 149.2, and 134.7 (each 2C). According to the HMBC correlations from H-2, H-6, H-8', and H-6' to C-7, both aromatic rings were attached to C-7. The 1H-1H COSY spectra of 9 showed aromatic proton correlations of H-7/H-8/H-8'/H-7', H-8/H-9, and H-8'/H-9', as well as the HMBC correlations from H-7 to C-8, C-8', and C-9, indicating the presence of a 2,3-dimethylbutane moiety (Figure 3). By comparison, the skeleton of 9 was found to be the same as that of kadangustin J [12].

According to the chemical shift of δ_C 67.3 (C-7'), a hydroxy group should be placed at C-7'. Four methoxy groups were located at C-3, C-5, C-3', and C-5, respectively, while C-4 and C-4' were substituted with hydroxy groups. Thus, the structure of compound 9 was determined to be 4,4-di-(4-hydroxy-3,5-dimethoxyphenyl)-2,3-dimethylbutanol and named gossypilignan A. As compound 9 was a 7,7-diaryl-8,8'-dimethylbutan-1-ol lignan, it had two chiral centers. Based on the investigation of Davidson et al., syn- and anti-isomers of such compounds can be distinguished based on the significant differences between their 1H NMR data [13]; therefore, as in the case of 9, both methyl groups were β-oriented, proving that this compound was a syn-isomer.

The molecular formula of 10 was determined as C_{22}H_{28}O_{7} by the HRESIMS pseudomolecular ion at m/z 427.1734 [M + Na]^+. The 1H NMR spectrum of 10 showed four aromatic hydrogens as two similar systems, one at δ_H 6.69 (2H, br s), and another at 6.63 (2H, br s), indicating the presence of two 1,3,4,5-tetrasubstituted benzene rings (Table 4). The chemical shifts observed for aromatic hydrogens along with the presence of four singlets corresponding to methoxy hydrogens at δ_H 2 × 3.84 and 2 × 3.86 (s, 3H each) indicated the presence of 3,5-dimethoxy-4-hydroxyphenyl groups in this compound. The 13C NMR data corroborated the structural determination of these aromatic rings. Moreover, 1H NMR spectral data suggested a nonsymmetric tetrahydrofuran lignan, through signals corresponding to two methyl groups at δ_H 1.00 (d, J = 6.4 Hz) and 0.63 (d, J = 7.0 Hz) in addition to the...
to two oxybenzyl methines at $\delta_H$ 4.64 (d, $J = 9.3$) and 5.47 (d, $J = 4.4$ Hz). The attachment of aromatic rings to the tetrahydrofuran ring was determined by an HMBC experiment. In the HMBC spectrum, interactions were observed between H-2’ and C-7’, and C-4’, between H-6’/C-4’ and C-2’, and between H-2 and C-7. These data indicated the presence of the two 3,5-dimethoxy-4-hydroxyphenyl structural parts at C-7 and C-7’, respectively. Based on previous literature data [14,15], the coupling constant of 9.3 Hz for the doublet at $\delta_H$ 4.64 (H-7) indicated that this hydrogen was in a trans configuration with the adjacent H-8, while the coupling constant of 4.4 Hz of H-7’ demonstrated its cis relationship with H-8’. NOE correlations confirmed the relative stereochemistry at the tetrahydrofuran ring as trans (C-7/C-8), cis (C-8/C-8’), and cis (C-8’/C-7’). Moreover, NOE effects proved the cis configuration of the aromatic group at C-7’ and methyl groups at C-9 and C-9’. These data permitted the establishment of the structure of the new tetrahydrofuran lignan 10 as rel-(7S,8R,7’S,8’S)-3,5,3’,5’-tetramethoxy-4,4’-dihydroxy-7,7’-epoxyxilignan and named gossypilignan B.

Figure 3. Selected $^1$H-$^1$H COSY (—) and HMBC (→) correlations of 9.

The known compounds were identified as 12-O-benzoyldeacetylmethaplexigenin, 9α-hydroxyxipinoserinol [16], naringenin [17], and quercitrin [18]. All compounds were isolated for the first time from the plant. Such polyoxypregnane ester derivatives were isolated previously, mainly from Asclepiadaceae species (e.g., Cynanchum wifordi and Leptadenia hastata) [9]. Though Euphorbia species are frequently characterized by the abundant presence of various terpenoids, this is only the second report of pregnanes from a plant belonging to the Euphorbiaceae family. Previously, two pregnane glycosides were identified from the aerial parts of Croton ruizianus. Their aglycon was 3β,14β,15β,16α-tetrahydroxypregnan-20-one, while the connecting sugar parts were either 3-O-β-D-Glu-(1→4)-β-D-Ole-(1→4)-β-D-Ole-(1→4)-β-D-Dig-(1→4)-β-D-Ole or 3-O-β-D-Ole-(1→4)-β-D-Dig-(1→4)-β-D-Dig-(1→4)-β-D-Ole (Ole—oleandrose; Dig—digitoxose) [19]. Pregnan glycosides isolated from E. gossypina var. coccinea were substituted with thevetose, cymarose, digitoxose, and glucose-containing linear sugar chains.

The 7,7’-diarylbutanol seco-lignans are an interesting class of lignans with both chemical and pharmacological importance. Cytotoxic, anti-HIV-1, and antioxidant activities have been previously reported for this class of natural products [12,20,21].
Pregnane glycosides are reported to possess various biological activities, an antiproliferative effect being one of the most important ones [22]. Amplexoeside A, isolated from an Asclepiadaceae species Asclepias amplexicaulis, showed antiproliferative activity in the KB assay. Condurangoglycoides identified from Marsdenia concurango were proved to be active against Sarcoma 180 and Ehrlich sarcoma in mice [23,24]. Pregnane glycosides (Ap and Ao) from Dregea volubilis showed activity against Ehrlich carcinoma [25]. Moreover, compounds with an antitumor effect were isolated from Aspidopterys obcordata, Caralluma dalzielii, C. negevensis, C. quadrangular, Cynanchum wilfordi, Desmidorchis flava, Gelsemium sempervirens, Marsdenia tenacissima, Periploca sepium, Solenostemma argel, and Stizophyllum riparium [8,26–28]. Although the molecular backbone of lignans consists of only two phenylpropane (C6–C3) units, they show an enormous structural diversity, and promising pharmacological effects. A considerable number of plant lignans (e.g., podophyllotoxin, sesamin, diphyllin, enterolactone, arctiin, matairesinol, and taxiresinol) were identified to possess antiproliferative activity [29]. Since, previously, several pregnane glycosides and lignans were reported to display strong antiproliferative activities, all isolated compounds belonging to these groups of special metabolites were tested for their antiproliferative properties against the HeLa cell line using the MTT assay. Doxorubicin and cisplatin were used as positive controls (IC$_{50}$ 0.02 ± 0.003 µM and 2.07 ± 0.07 µM, respectively). Among the tested compounds, only euphogossypin A (1) exerted weak antiproliferative activity (IC$_{50}$ 52.4 ± 0.23 µM), while the others proved to be inactive (Table S1).

3. Materials and Methods

3.1. General Experimental Procedures

NMR spectra were recorded in CDCl$_3$, CD$_3$OD, and C$_5$D$_5$N on a Bruker Avance DRX 500 spectrometer (Billerica, MA, USA) at 500 MHz (1H) and 125 MHz (13C). The signals of the deuterated solvents were taken as reference. The chemical shift values (δ) were given in ppm and coupling constants (J) were in Hz. Two-dimensional (2D) experiments were performed with standard Bruker software. In the COSY, HSQC, and HMBC experiments, gradient-enhanced versions were used. High-resolution MS spectra were acquired on a Thermo Scientific Q-Exactive Plus Orbitrap mass spectrometer (Waltham, MA, USA) equipped with ESI ion source in positive ionization mode. The data were acquired and processed with MassLynx software.

Column chromatography (CC) was performed on polyamide (MP Biomedicals, Irvine, CA, USA). Normal-phase vacuum liquid chromatography (VLC) was carried out on silica gel (Kieselgel 60 GF$_{254}$, 15 µm, Merck, Darmstadt, Germany). Thin-layer chromatography was performed on Kieselgel 60 RP-18 F$_{254}$ and Kieselgel 60 F$_{254}$ (Merck, Darmstadt, Germany). Spots were detected under UV light (245 nm and 336 nm) and made visible with vanillin sulfuric acid reagent and heating at 105 °C for 1 min. The high-performance liquid chromatography (HPLC) separation was carried out on a Waters HPLC (Waters 600 controller, Waters 600 pump, and Waters 2998 photodiode array detector), using RP (LiChrospher RP-18, 5 µm, 250 × 4 mm, Merck, Darmstadt, Germany) column. In the case of the RP-HPLC separation, the mobile phase consisted of MeOH (solvent A) and H$_2$O (solvent B). The flow rate was 1 mL/min. The data were acquired and processed with the Empower software.

All solvents used for CC were of at least analytical grade (VWR Ltd., Szeged, Hungary). Ultra-pure water was prepared with a Milli-Q water purification system (Millipore, France).

3.2. Plant Material

Aerial parts of Euphorbia gossypina var. coccinea Pax. were collected in Kenya (GPS coordinates 1°24′24.31777″ S, 36°42′53.86125″ E), Africa, in July 2018, and identified by Patrick Chalo Mutiso, a taxonomist (Department of Biological Sciences, Faculty of Science and Technology, University of Nairobi). A voucher specimen (no. UON 2018/249) was deposited at the Herbarium of the School of Biological Sciences, University of Nairobi, Kenya.
3.3. Isolation of Compounds

The dried and ground aerial parts of *E. gossypina* var. *coccinea* (1 kg) were extracted with methanol at room temperature. After concentration, the extract (45 g) was dissolved in 50% aqueous methanol, and solvent–solvent partitions were performed with hexane, CHCl₃, and EtOAc. The CHCl₃ fraction (28.6 g) was purified by polyamide column chromatography using MeOH–H₂O (4:1) to remove chlorophyll. Thereafter, the yielded fraction (22.8 g) was purified by VLC on silica gel with a gradient system of cyclohexane–EtOAc–EtOH (from 8:2:0 to 6:3:1) and CHCl₃–MeOH (from 9:1 to 1:1). The TLC determination and combination of the fractions afforded 20 main fractions (Fr. 1–20). Fraction 9 (1.4 g) was further chromatographed by RP-VLC using MeOH–H₂O gradient solvent system (8:2–2:8), and 9 fractions (Fr. 9/1–9) were obtained. Fraction 9/3 (87.9 mg) was subjected to preparative TLC using CHCl₃–MeOH (8:2) as eluent and was, subsequently, purified by RP-HPLC. Gradient elution was applied, starting at 10% A (methanol) and 90% B (H₂O) for 1 min, then linearly increased to 50% A (in 10 min) to yield compound 1 (tᵣ = 3.1 min, 2.6 mg). Fraction 10 (1.6 g) was separated by NP-VLC using a toluene–acetone gradient system (from 9:1 to 6:4) to obtain 9 subfractions (Fr. 10/1–9). Fr. 10/4 (371 mg) was chromatographed by NP-VLC using the gradient system of toluene–acetone–EtOH (from 9:1 to 1:1) to yield 11 subfractions (Fr. 10/4/1–11). Fraction 11 (4.9 g) was separated by RP-VLC using MeOH–H₂O (8:2) as eluent and was, subsequently, purified by RP-HPLC by using gradient elution, started at 10% A (methanol) and 90% B (H₂O) for 1 min, then linearly increased to 50% A (in 10 min) to yield compound 2 (tᵣ = 7.2 min, 24.3 mg). Fr. 10/6 (123 mg) was separated by RP-TLC using MeOH–H₂O (8:2) as solvent system and compound 1 (11.2 mg) was obtained. Fraction 11 (4.9 g) was chromatographed by NP-VLC using the gradient system of toluene–acetone (from 9:1 to 1:1) to yield 11 subfractions (Fr. 11/1–11). Fraction 11/9 (193.5 mg) was purified by RP-TLC using MeOH–H₂O (8:2) as an eluent to yield compound 2 (19.7 mg) and two subfractions (Fr. 11/9/1 (8.1 mg) and 2 (6.9 mg)). Both fractions were purified by RP-HPLC (the gradient started at MeOH–H₂O (2:8) for 1 min, then linearly ramped up to 1:1 in 10 min and held 0.5 min, then returned to the initial conditions within 1 min, and kept for 2 min) to yield compounds 8 (tᵣ = 5.2 min, 6.4 mg) and 7 (tᵣ = 6.1 min, 5.1 mg). Fr. 13 (165 mg) was purified by NP-TLC using CHCl₃–MeOH (85:15) as mobile phase. Fr. 10/5 (188 mg) was purified by RP-TLC using MeOH–H₂O (8:2) as eluent, and further purified by RP-HPLC by using gradient elution, started at 10% A (methanol) and 90% B (H₂O) for 1 min, then linearly increased to 50% A (in 10 min) to yield compound 9 (tᵣ = 7.3 min, 12.1 mg). Fr. 10/6 (123 mg) was separated by RP-TLC using MeOH–H₂O (8:2) as solvent system and compound 1 (11.2 mg) was obtained. Fraction 11 (4.9 g) was chromatographed by NP-VLC using the gradient system of toluene–acetone (from 9:1 to 1:1) to yield 11 subfractions (Fr. 11/1–11). Fraction 11/9 (193.5 mg) was purified by RP-TLC using MeOH–H₂O (8:2) as an eluent to yield compound 2 (19.7 mg) and two subfractions (Fr. 11/9/1 (8.1 mg) and 2 (6.9 mg)). Both fractions were purified by RP-HPLC (the gradient started at MeOH–H₂O (2:8) for 1 min, then linearly ramped up to 1:1 in 10 min and held 0.5 min, then returned to the initial conditions within 1 min, and kept for 2 min) to yield compounds 8 (tᵣ = 5.2 min, 6.4 mg) and 7 (tᵣ = 6.1 min, 5.1 mg). Fr. 13 (165 mg) was purified by NP-TLC using CHCl₃–MeOH (85:15) as mobile phase to isolate compound 4 (12.7 mg). Fraction 15 (5.9 g) was separated by RP-VLC using a gradient system of MeOH–H₂O (from 9:1 to 9:1) to yield 7 subfractions (Fr. 15/1–7). Fraction 15/3 (50 mg) was subjected to an NP-TLC using toluene–acetone (1:1) as an eluent to obtain naringenin (5 mg). Fraction 15/6 (75 mg) was subjected to RP-TLC using MeOH–H₂O (7:3) to yield quer cetin (8.9 mg). Fraction 15/7 (329 mg) was purified by RP-HPLC using MeOH–H₂O (8:2) isocratic solvent system to obtain 12-O-benzoyldeacylmetaplexigenin (tᵣ = 11 min, 47.1 mg). Fraction 15/8 (75 mg) was purified by RP-HPLC (the gradient started at MeOH–H₂O (2:8) for 1 min, then linearly ramped up to 1:1 in 10 min and held 0.5 min, then returned to the initial conditions within 1 min and kept for 2 min) to yield compound 6 (tᵣ = 5.5 min, 13.9 mg). Fr. 16 (1.6 g) was subjected to an NP-VLC using CHCl₃–MeOH gradient system (from 98:2 to 1:1) to yield 9 subfractions (Fr. 16/1–9). Fr. 16/6 (106 mg) was further purified by RP-HPLC using MeOH–H₂O (7:3) isocratic solvent system to obtain compound 5 (tᵣ = 7.2 min, 24.3 mg).

3.3.1. Euphogossypin A (1)

White amorphous powder; [α]D²⁵ +12 (c 0.1, MeOH); HRESIMS m/z: 955.4660 [M + Na]+ (calcld for C₄₆H₇₂O₁₇Na, 955.4662); ¹H (CDCl₃, 500 MHz) and ¹³C NMR (CDCl₃, 125 MHz) data, see Table 1.

3.3.2. Euphogossypin B (2)

White amorphous powder; [α]D²⁵ +24 (c 0.2, MeOH); HRESIMS m/z: 927.4352 [M + Na]+ (calcld for C₄₇H₆₈O₁₇Na, 927.4349); ¹H (C₅D₅N, 500 MHz) and ¹³C NMR ((C₅D₅N, 125 MHz) data, see Table 1.
3.3.3. Euphogossypin C (3)
White amorphous powder; $[\alpha]_{D}^{25} +5$ (c 0.1, MeOH); HRESIMS m/z: 941.4508 [M + Na]$^+$ (calcd for C$_{48}$H$_{70}$O$_{17}$Na 941.4510); $^1$H (CD$_3$OD, 500 MHz) and $^{13}$C NMR (CD$_3$OD, 125 MHz) data, see Table 1.

3.3.4. Euphogossypin D (4)
White amorphous powder; $[\alpha]_{D}^{25} +63$ (c 0.15, MeOH); HRESIMS m/z: 1103.5029 [M + Na]$^+$ (calcd for C$_{54}$H$_{80}$O$_{22}$Na, 1103.5033); $^1$H (CD$_3$OD, 500 MHz) and $^{13}$C NMR (CD$_3$OD, 125 MHz) data, see Table 2.

3.3.5. Euphogossypin E (5)
White amorphous powder; $[\alpha]_{D}^{25} 0$ (c 0.15, MeOH); HRESIMS m/z: 1089.4869 [M + Na]$^+$ (calcd for C$_{53}$H$_{78}$O$_{22}$Na, 1089.4877); $^1$H (CD$_3$OD, 500 MHz) and $^{13}$C NMR (CD$_3$OD, 125 MHz) data, see Table 2.

3.3.6. Euphogossypin F (6)
White amorphous powder; $[\alpha]_{D}^{25} +3$ (c 0.15, MeOH); HRESIMS m/z: 1103.5029 [M + Na]$^+$ (calcd for C$_{54}$H$_{80}$O$_{22}$Na, 1103.5033); $^1$H (CD$_3$OD, 500 MHz) and $^{13}$C NMR (CD$_3$OD, 125 MHz) data, see Table 2.

3.3.7. Euphogossypin G (7)
White amorphous powder; $[\alpha]_{D}^{25} +12$ (c 0.05, MeOH); HRESIMS m/z: 865.4188 [M + Na]$^+$ (calcd for C$_{42}$H$_{66}$O$_{17}$Na, 865.4192); $^1$H (CDCl$_3$, 500 MHz) and $^{13}$C NMR (CDCl$_3$, 125 MHz) data, see Table 3.

3.3.8. Euphogossypin H (8)
White amorphous powder; $[\alpha]_{D}^{25} +33$ (c 0.15, MeOH); HRESIMS m/z: 837.4238 [M + Na]$^+$ (calcd for C$_{41}$H$_{66}$O$_{16}$Na, 837.4243); $^1$H (CDCl$_3$, 500 MHz) and $^{13}$C NMR (CDCl$_3$, 125 MHz) data, see Table 3.

3.3.9. Gossypilignan A (9)
Pale yellow amorphous solid; $[\alpha]_{D}^{25} −13$ (c 0.1, MeOH); HRESIMS m/z: 429.1889 [M + Na]$^+$ (calcd for C$_{22}$H$_{30}$O$_7$Na, 429.1884); $^1$H (CD$_3$OD, 500 MHz) and $^{13}$C NMR (CD$_3$OD, 125 MHz) data, see Table 4.

3.3.10. Gossypilignan B (10)
White amorphous powder; $[\alpha]_{D}^{25} −5$ (c 0.05, MeOH); HRESIMS m/z: 427.1734 [M + Na]$^+$ (calcd for C$_{22}$H$_{28}$O$_7$Na, 427.1727); $^1$H (CD$_3$OD, 500 MHz) and $^{13}$C NMR (CD$_3$OD, 125 MHz) data, see Table 4.

3.3.11. 12-O-Benzoyldeacylmetaplexigenin
$^1$H NMR (in CDCl$_3$) $\delta$H 1.15 (3H, s, Me-19), 1.15, 1.90 (2H, m, H-1), 1.55 (3H, s, Me-18), 1.56, 1.83 (2H, m, H-2), 1.60 (1H, m, H-9), 1.96 (2H, m, H-11), 2.03 (2H, m, H-15), 2.07 (3H, s, Me-21), 2.25 (2H, m, H-7), 2.30–2.39 (2H, m, H-4), 1.92, 2.86 (2H, m, H-16), 3.57 (1H, m, H-3), 4.86 (1H, dd, $J$ = 10.2, 5.6 Hz, H-12), and 5.39 (1H, br s, H-6); $^{13}$C NMR see Table 1.

3.4. Antiproliferative Assays
3.4.1. Cell Line
Human cervix carcinoma (HeLa) cells were cultured in Eagle’s Minimal Essential Medium (EMEM, containing 4.5 g/L glucose) supplemented with a non-essential amino acid mixture, a selection of vitamins, and 10% heat-inactivated fetal bovine serum. The cell line was detached with 0.25% trypsin and 0.02% EDTA for 5 min at 37 °C. The cell line was purchased from LGC Promochem, Teddington, England.
3.4.2. Antiproliferative Assay

The antiproliferative assay of the isolated compounds (1–3, 5–12) against the human cervix carcinoma (HeLa) cell line was performed by MTT, using cisplatin and doxorubicin as positive controls. This assay was carried out as previously described [30,31].

4. Conclusions

In this article, nine polyoxypregnane ester derivatives, including euphogossypins A–H (1–8) as new natural products, two new lignans (gossypilignans A (9) and B (10)), and 12-O-benzoylexacyclometaplexigenin (11), 9α-hydroxypinoresinol (12), naringenin (13), and quercitrin (14) as known compounds, were characterized from the aerial parts of E. gossypina var. coccinea. Their planar structures were elucidated by comprehensive spectroscopic data. All compounds were isolated for the first time from the plant. Although previously several pregnane glycosides and lignans have been found to be active as antiproliferative agents, none of the compounds isolated from E. gossypina var. coccinea showed remarkable antiproliferative activity against the HeLa cells. Our findings enrich the knowledge of special metabolites of Euphorbia species.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/plants11101299/s1, Figures S1–S58: One-dimensional and two-dimensional NMR spectra of isolated compounds (1–10); Table S1: Antiproliferative activity of the isolated compounds (1–3, 5–12) in HeLa cell line.

Author Contributions: Conceptualization, A.V.; methodology, A.V.; software, N.S. and G.S.; investigation, R.H., N.K., R.B., N.S., C.Z.D., P.W.M. and G.S.; resources, J.H.; writing—original draft preparation, R.H. and A.V.; writing—review and editing, A.V., N.K. and J.H.; project administration, J.H.; funding acquisition, J.H. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the National Research, Development and Innovation Office, Hungary (K135845), the UNKP-21-3-SZTE-265 New National Excellence Program, and TKP2021-EGA-32 of the Ministry of Innovation and Technology of Hungary from the source of the National Research, Development and Innovation Fund.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data is contained within the article and Supplementary Material.

Acknowledgments: The authors acknowledge Patrick Chalo Mutiso, a taxonomist (Department of Biological Sciences, Faculty of Science and Technology, University of Nairobi), for the collection and identification of plant material.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Vasas, A.; Hohmann, J. Euphorbia Diterpenes: Isolation, Structure, Biological Activity, and Synthesis (2008–2012). Chem. Rev. 2014, 114, 8579–8612. [CrossRef] [PubMed]
2. Shi, Q.W.; Su, X.H.; Kiyota, H. Chemical and pharmacological research of the plants in genus Euphorbia. Chem. Rev. 2008, 108, 4295–4327. [CrossRef] [PubMed]
3. Euphorbia gossypina. Available online: https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:346654-1 (accessed on 31 March 2022).
4. Sharma, P.; Singh, G. A review of plant species used to treat conjunctivitis. Phytother Res. 2002, 16, 1–22. [CrossRef] [PubMed]
5. Schmelzer, G.H.; Gurib-Fakim, A. Plant Resources of Tropical Africa 11 (1), Medicinal Plants1; PROTA Foundation/Backhuys Publisher/CTA: Wageningen, The Netherlands, 2008; Volume 11, p. 300.
6. Catley, A.; Mohammed, A.A. Ethnoveterinary knowledge in Sanaag region, Somaliland (Part II): Notes on local methods of treating and preventing livestock disease. Nomadic Peoples 1996, 39, 135–145.
7. Araya, J.J.; Binns, F.; Kindscher, K.; Timmermann, B.N. Verticillosides A–M: Polyoxynated pregnane glycosides from Asclepias verticillata L. Phytochemistry 2012, 78, 179–189. [CrossRef]
8. Si, Y.; Sha, X.S.; Shi, L.L.; Wei, H.Y.; Jin, Y.X.; Ma, G.X. Review on pregnane glycosides and their biological activities. *Phytochem. Lett.* **2022**, *47*, 1–17. [CrossRef]

9. Tsukamoto, S.; Hayashi, K.; Mitsuhashi, H. Studies on the constituents of Asclepiadaceae plants. LX. Further studies on glycosides with a novel sugar chain containing a pair of optically isomeric sugars, d- and l-cymarose, from *Cynanchum wilfordii*. *Chem. Pharm. Bull.* **1985**, *33*, 2294–2904. [CrossRef]

10. Kiem, P.V.; Yen, D.T.H.; Hung, N.V.; Nhiem, N.X.; Tai, B.H.; Trang, D.T.; Yen, P.H.; Ngoc, T.M.; Minh, C.V.; Park, S.; et al. Five new pregnane glycosides from *Gymnema sylvestre* and their α-glucosidase and α-amylase inhibitory activities. *Molecules* **2020**, *25*, 2525. [CrossRef]

11. Aquino, R. New polyoxypregnane ester derivatives from *Leptadenia hastata*. *J. Nat. Prod.* **1996**, *59*, 555–564. [CrossRef]

12. Gao, X.M.; Pu, J.X.; Huang, S.X.; Yang, L.M.; Huang, H.; Xiao, W.L.; Zheng, Y.T.; Sun, H.D. Lignans from *Kadsura angustifolia*. *J. Nat. Prod.* **2008**, *71*, 558–563. [CrossRef]

13. Davidson, S.J.; Rye, C.E.; Barker, D. Using NMR to determine the relative stereochemistry of 7,7-diaryl-8,8′-dimethylbutan-1-ol lignans. *Phytochem. Lett.* **2015**, *14*, 138–142. [CrossRef]

14. Yue, J.M.; Chen, Y.Z.; Hua, S.M.; Cheng, J.L.; Cui, Y.X. Ganschisandrine, a lignan from *Schisandra sphenanthera*. *Phytochemistry* **1989**, *28*, 1774–1776.

15. Da Silva Filho, A.A.; Albuquerque, S.; e Silva, M.L.A.; Eberlin, M.N.; Tomazela, D.M.; Bastos, J.K. Tetrahydrofuran lignans from *Nectandra megapotamica* with trypanocidal activity. *J. Nat. Prod.* **2004**, *67*, 42–45. [CrossRef][PubMed]

16. Abe, F.; Yamauchi, T. 9α-hydroxyphineosinol, 9α-hydroxyphineosinol related lignans from *Allamanda neriifolia*. *Phytochemistry* **1988**, *27*, 575–577. [CrossRef]

17. Cordenonsi, L.M.; Sponchiado, R.M.; Campanharo, S.C.; Garcia, C.V.; Raffin, R.P.; Schapoval, E.E.S. Study of flavonoids presente in Pomelo (*Citrus maxima*) by DSC, UV-VIS, IR, 1H and 13C NMR and MS. *Drug Anal. Res.* **2017**, *1*, 31–37. [CrossRef]

18. Zhong, X.N.; Otsuka, H.; Ide, T.; Hirata, E.; Takushi, A.; Takeda, Y. Three flavonol glycosides from leaves of *Myrsine sequinii*. *Phytochemistry* **1997**, *46*, 943–946. [CrossRef]

19. Piacenti, S.; Belisario, A.B.; Castillo, H.D.; Pizzia, C.; Feo, V.D. *Croton ruizianus*: Platelet proaggregating activity of two new pregnane glycosides. *J. Nat. Prod.* **1998**, *61*, 318–322. [CrossRef]

20. Xu, L.J.; Huang, F.; Chen, S.B.; Li, L.N.; Chen, S.L.; Xiao, P.G. A cytotoxic neolignan from *Schisandra propinqua* (Wall.) Baill. *J. Integr. Plant Biol.* **2008**, *48*, 1493–1497. [CrossRef]

21. Huang, F.; Xu, L.; Shi, G. Antioxidant isolated from *Schisandra propinqua* (Wall.) Baill. *Biol. Res.* **2009**, *42*, 351–356. [CrossRef]

22. Deepak, D.; Srivastav, S.; Khare, A. Pregnanol esters. In *Fortschritte der Chemie Organischer Naturstoffe/Progress in the Chemistry of Organic Natural Products*; Springer: Vienna, Austria, 1997; Volume 71. [CrossRef]

23. Hayashi, K.; Wada, K.; Mitsuhashi, H.; Bando, H.; Takase, M.; Terada, S.; Koide, Y.; Aiba, T.; Narita, T.; Mizuno, D. Antitumor active glycosides from Condrouranus cortex. *Chem. Pharm. Bull.* **1980**, *28*, 1954–1958. [CrossRef]

24. Hayashi, K.; Wada, K.; Mitsuhashi, H.; Bando, H.; Takase, M.; Terada, S.; Koide, Y.; Aiba, T.; Narita, T.; Mizuno, D. Further investigation of antitumor condurangoglycosides with C-18 oxygenated aglycone. *Chem. Pharm. Bull.* **1981**, *29*, 2725–2730. [CrossRef][PubMed]

25. Yoshimura, S.I.; Narita, H.; Hayashi, K.; Mitsuhashi, H. Studies on the constituents of Asclepiadaceae plants. LVI. Isolation of new antitumor-active glycosides from *Dregea volubilis* (L.) Benth. *Chem. Pharm. Bull.* **1983**, *31*, 3971. [CrossRef][PubMed]

26. Yu, N.; Banerjee, S.; Mandal, N.B.; Sahu, N.P. Pregnan glycosides. *Nat. Prod. Commun.* **2006**, *1*, 665–695. [CrossRef]

27. Plaza, A.; Perrone, A.; Balestri, M.L.; Felice, F.; Balestri, C.; Hamed, A.I.; Piazza, C.; Piacente, S. New unusual pregnane glycosides with antiproliferative activity from *Solenostemma argel*. *Steroids* **2005**, *70*, 594–603. [CrossRef]

28. Hunag, I.J.; Wang, B.; Zhang, J.X.; Yan, C.; Mu, S.Z.; Hao, X.J. Studies on cytotoxic pregnane sapogenins from *Cynanchum wilfordii*. *Fitoterapia* **2015**, *101*, 107–116. [CrossRef]

29. Saleem, M.; Kim, H.J.; Ali, M.S.; Lee, Y.S. An update on bioactive plant lignans. *Nat. Prod. Rep.* **2005**, *22*, 696–716. [CrossRef]

30. Stefko, D.; Kúsz, N.; Szemereádi, N.; Barta, A.; Spengler, G.; Berkecz, R.; Hofmann, J.; Vasas, A. Unique phanethrenes from *Juncus ensifolius* and their anti-proliferative and synergistic effects with the conventional anticancer agent doxorubicin against human cancer cell lines. *Pharmaceutics* **2012**, *4*, 608. [CrossRef]

31. Bacher, F.; Wittmann, C.; Nové, M.; Spengler, G.; Maré, M.A.; Enyedy, E.A.; Darvasiová, D.; Rapta, P.; Reinere, T.; Arion, V.B. Novel latonduine derived proligands and their copper(II) complexes show cytotoxicity in the nanomolar range in human colon adenocarcinoma cells and in vitro cancer selectivity. *Dalton Trans.* **2019**, *48*, 10464. [CrossRef]